Chae Ok Yun, Founder & CEO – GeneMedicine

30.06.2022
Chae Ok Yun Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of its candidates getting close to phase II clinical trials and the construction of a new manufacturing facility that will enable GeneMedicine to grow its CDMO business.
Our preclinical data and clinical experience with our pipelines have been highly promising, and we are eager to advance our clinical trials to later stages.
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Korea, Asia, GeneMedicine, Biotech, Cell & Gene Therapy, Oncolytic Virus

Related Interviews

Stephen Yoo – CEO & CSO, STCube Pharmaceuticals

Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach,…

Korea / Exploring the Regenerative and Anti-Inflamatory Potential of Exosomes

ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…

Exclusive / Samsung Biologics CEO Talks 35% Annual Growth, CDMO Industry Trends & Korea's BioInnovation Agenda

After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…

Latest Report

Related Articles

Korea / Medtronic Continues Diabetes Pivot with USD 738m Acquisition of Insulin Patch Maker EOFlow

Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market.  …

Korea / Boston Benchmark; Top Biotechs; Merck Expansion; Medtronic Acquisition

A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…

Korea / Samsung Biologics Rides CDMO Expansion Wave with New USD 1.5 Billion Investment

As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…

Related Content

Korea
Asia
GeneMedicine
Biotech
Cell & Gene Therapy
Oncolytic Virus